Drug treatment of epilepsy in the 1990s. Achievements and new developments

Drugs

Volumn 52, Issue 4, 1996, Pages 483-493

  Sabers, Anne ^a   Gram, Lennart ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BROMIDE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

APLASTIC ANEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TOXICITY; ENZYME INDUCTION; EPILEPSY; FOCAL EPILEPSY; GRAND MAL EPILEPSY; HUMAN; META ANALYSIS; NONHUMAN; PROGNOSIS; PSYCHOSIS; REVIEW; SEIZURE; SIDE EFFECT; SKIN ALLERGY; TREATMENT PLANNING;

EID: 0029800876     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652040-00002     Document Type: Review

References (122)

1. Locock C. Discussion of paper by EH Sieveking: analysis of 52 cases of epilepsy observed by the author. Lancet 1857; 1: 527
2. Tomson T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol 1984; 41: 830-4
3. Cramer J, Mattson RH, Prevey MC, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7
4. Persson L, Ben-Menachem E, Bentsson E, et al. Differences in side effects between a conventional carbamazepine preparation and a slow release preparation of carbamazepine. Epilepsy Res 1990; 6: 134-40
5. Canger R, Altamura AC, Belvedere O, et al. Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. Acta Neurol Scand 1990; 82: 9-13
6. McKee PJW, Backlaw J, Butler R, et al. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. Br J Clin Pharmacol 1991; 32: 99-104
7. McKee PJW, Blacklaw J, Carswell A, et al. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients. Br J Clin Pharmacol 1993; 36: 257-61
8. Gram L, Bentsen KD, Parnas H, et al. Controlled trials in epilepsy. A review. Epilepsia 1982; 23: 491-519
9. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondary generalised tonic-clonic seizures. N Engl J Med 1985; 313: 145-51
10. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalised tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765-71
11. Richens A, Davidson DLW, Cartlidge NEF, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 682-7
12. Heller AJ, Chesterman P, Elwes RDC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44-50
13. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in pediatric epilepsy. Dev Med Child Neurol 1995; 37: 97-108
14. Porter RJ, Cereghino JJ, Gladding GD, et al. Antiepileptic drug development program. Cleve Clin J Med 1984; 51: 293-305
15. Rogowski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with considerations of promising developmental stage compounds. Pharmacol Rev 1990; 42: 223-6
16. Theodore WH, Raubertas RF, Porter RJ, et al. Felbamate: a clinical trial for complex partial seizures. Epilepsia 1991; 32: 392-7
17. Gram L, Wulff K, Rasmussen KE, et al. Valproate sodium: a controlled clinical trial including monitoring of serum levels. Epilepsia 1977; 18: 141-8
18. Leber P. Hazards of inference: the active control investigation. Epilepsia 1989; 30: S57-63
19. Leber P. The implicit assumption of active controlled trials (a critical examination). Control Clin Trials 1983; 14: 133
20. Schmidt D. Evaluation of clinical efficacy in antiepileptic drug trials. In: Pisani F, Perucca E, Avanzini G, editors. New antiepileptic drugs. Suppl. 3. Amsterdam: Elsevier, 1991: 69-78
21. Pledger GW, Kramer LD. Clinical trials of investigational antiepileptic drugs: monotherapy designs. Epilepsia 1991; 32: 216-21
22. Cereghino JJ. Clinical trial design for antiepileptic drugs. Ann Neurol 1992; 32: 393-4
23. Gram L, Schmidt D. Innovative designs of controlled clinical trials in epilepsy. Epilepsia 1993; 34 Suppl. 7: S1-6
24. Pledger GW, Schmidt D. Evaluation of antiepileptic drug efficacy: a review of clinical trial design. Drugs 1994; 48: 498-509
25. Sachdeo R, Kramer LD, Roseberg A, et al. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992; 32: 386-92
26. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: an active control trial. Neurology 1993; 43: 688-92
27. Bourgeois B, Leppik IE, Sackellares JC, et al. Felbamate: a double-blind controlled trial in patients undergoing presurgical evalaution of partial seizures. Neurology 1993; 43: 693-6
28. Kälviäinen R, Keränen T, Riekkinen PJ. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs 1993; 46 (6): 1009-24
29. Patsalos PN, Duncan JS. New antiepileptic drugs: a review of their current status and clinical potential. CNS Drugs 1994; 2 (1): 40-77
30. Sabers A, Gram L. Progress in the medical treatment of epilepsy: an overview of new antiepileptic drugs. Eur J Neurol 1995; 1: 189-202
31. McLean MJ, Schmutz M, Wamil AW, et al. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35 Suppl. 3: S5-9
32. Bülau P, Stoll KD, Fröscher W. Oxcarbazepine versus carbamazepine. In: Wolf P, Dam M, Janz D, editors. Advances in epileptology. New York: Raven Press, 1987: 331-6
33. Reinikainen KJ, Keränen T, Halonen T, et al. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987; 1: 284-9
34. Dam M, Ekberg R, Løyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6
35. Houtkooper MA, Lammertsma A, Meyer JWA, et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine. Epilepsia 1987; 28 (6): 693-8
36. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-7
37. van Parys JPA, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal®) on a named-patient basis. Epilepsy Res 1994; 19: 79-85
38. Grant SM, Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43 (6): 873-88
39. Schechter PJ, Hanke NFJ, Grove J, et al. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology 1984; 34: 182-6
40. Ben-Menachem E. Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans. Epilepsia 1989; 30 Suppl. 3: S12-4
41. Mumford JP, Dam M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989; 27 Suppl. 1: S101-7
42. Chiron C, Dulac O, Beaumont D, et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991; 6 Suppl. 2: S52-9
43. Kälviäinen R, Äikiä M, Saukkonen AM, et al. Vigabatrin vs carbamazepin monotherapy in patients with newly diagnosed epilepsy. Arch Neurol 1995; 52: 989-96
44. Michelucci R, Tassinari CA. Response to vigabatrin in relation to seizure type. Br J Clin Pharmacol 1989; 27 Suppl. 1: 119S-24S
45. Remy C, Beaumont D. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. Br J Clin Pharmacol 1989; 27 Suppl. 1: 125S-9S
46. Dodrill CB, Arnett JL, Sommerville KW, et al. Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 1993; 43: 2501-7
47. Ring HA, Crellin R, Reynolds EH. Vigabatrin and depression. J Neurol Neurosurg Psychiatry 1993; 56: 925-8
48. Sander JWAS, Hart YM, Trimble MR, et al. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991; 54: 435-9
49. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic proberties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926
50. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27 (5): 490-7
51. Binnie CD, Debets RMC, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989; 4: 222-9
52. Jawad S, Richens A, Goodwin G, et al. Controlled trial of lamotrigine (Lamictal®) for refractory partial seizures. Epilepsia 1989; 30 (3): 356-63
53. Sander JWAS, Patsalos PN, Oxley JR, et al. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990; 6: 221-6
54. Sander JWAS, Trevisol-Bittencourt PC, Hart YM, et al. The efficacy and long term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990; 7: 226-9
55. Loiseau P, Yuen AWC, Duché B, et al. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990; 7: 136-45
56. Timmings PL, Richens A. Lamotrigine in primary generalized epilepsy. Lancet 1992; 339: 1300-1
57. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34 (2): 312-22
58. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, crossover trial. Epilepsia 1994; 35: 113-21
59. Bisgaard C, Dalby M, Mai J. Lamictal as add-on antiepileptic drug in 210 patients with resistant epilepsy [abstract]. Epilepsia 1994; 35 Suppl. 7: 98
60. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35 (2): 359-67
61. Hirsch E, Dutoya V, Strumia S, et al. Lamotrigine and generalized epileptic syndromes [abstract]. Epilepsia 1995; 36 Suppl. 3: S112
62. Mai J, Sørensen T. Experience with lamotrigine in mentally retarded epilepsy patients [abstract]. Epilepsia 1995; 36 Suppl. 3: S115
63. Brodie MJ, Richens A, Yuen AWC, et al. Double-blind comparison of lamotrigine and carbamazepine in newly-diagnosed epilepsy. Lancet 1995; 345: 476-9
64. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DGA, et al. Acute effect of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986; 27: 248-54
65. Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: single dose pharmacokinetics, and initial one week experience in refractory seizures. Epilepsy Res 1987; 1: 194-201
66. Besag FMC, Subel B, Pool F, et al. Carbamazepine toxicity with lamotrigine: a pharmacokinetic or pharmacodynamic interaction [abstract]. Epilepsia 1994; 35 Suppl. 7: 73
67. Fitton A, Goa K. Lamotrigine: an update of its pharmacology and its therapeutic use in epilepsy. Drugs 1995; 50 (4): 691-713
68. Taylor CP. Emerging perspectives on mechanism of action of gabapentin. Neurology 1994; 44 Suppl. 5: S10-6
69. Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46 (3): 409-27
70. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335: 1114-7
71. Bruni J, Saunders M, Anhut H, et al. Efficacy and safety of gabapentin (Neurontin): a multicenter, placebo-controlled, double-blind study [abstract]. Neurology 1991; 41 Suppl. 1: 330-1
72. Leppik IE, Shellenberger MK, Anhut H. Two open-label, multicenter studies of safety and efficacy of gabapentin as add-on therapy in patients with refractory partial seizures [abstract]. Epilepsia 1992; 33 Suppl. 3: 117
73. Ojemann LM, Wilensky AJ, Temkin NR, et al. Long-term treatment with gabapentin for partial epilepsy. Epilepsy Res 1992; 13: 159-65
74. US Gabapenlin Study Group No. 5, Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993; 43: 2292-8
75. US Gabapentin Study Group. The long-term safety and efficacy of gabapentin (Neurontin®) as add-on therapy in drug resistent partial epilepsy. Epilepsy Res 1994; 18: 67-73
76. Anhut H, Ashman P, Feuerslein TJ, et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 1994; 35 (4): 795-801
77. Anhut H, Greiner M, Möckel V, et al. Gabapenlin (Neurontin) as monotherapy in newly diagnosed patients with partial epilepsy [abstract]. Epilepsia 1995; 36 Suppl. 3: S119
78. Garofalo E, Hayes A, Greeley C, et al. Gabapentin (Neurontin) monotherapy in patients with medically refractory partial scizures: an open-label extension study [abstract]. Epilepsia 1995; 36: S119
79. Grain L. Tiagabine: a novel drug with a GABAergic mechanism of action. Epilepsia 1994; 35 Suppl. 5: S85-7
80. Braestrup C, Nielsen EB, Sonnenwald U, et al. (R)-N-[4.4-bis(3-metyl-2-thienyl) but-3-en-1-yl]nipecotic acid binds with high affinity to the brain GABA uptake carrier. J Neurochem 1990; 54: 639-43
81. Nielsen EB, Suzdak PD, Andersen KE, et al. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991; 196: 257-66
82. Fink-Jensen A, Suzdak PD, Swedberg MDB, et al. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rars. Eur J Pharmacol 1992; 220: 197-201
83. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995; 21: 37-42
84. Lassen LC, Sommerville K, Mengel HB, et al. Summary of five controlled trials with tiagabine as adjunctive treatment [abstract]. Epilepsia 1995; 36 Suppl. 3: S148
85. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structually novel anticonvulsant. Epilepsia 1994; 35 (2): 450-60
86. Mikkelsen M, Dam M, Östergaard L. Topiramate as add-on therapy in refractory partial epilepsy [abstract]. Seizure 1992; 1 Suppl. A: 7/31
87. Engelskjon T, Johannessen SI, Kloster R, et al. Topiramate in the treatment of refractory partial epilepsy - an efficacy and tolerance study [abstract]. Seizure 1992; 1 Suppl. A: 7/16
88. Faught E, Kuzniecky R, Richardson D, et al. The dose-response relationship for topiramate in partial onset seizures [abstract]. Seizure 1992; 1 Suppl. A: 7/17
89. Sharief MK, Sander JW, Patsalos PN, et al. Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia 1993; 34 Suppl. 6: 41
90. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ube L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995; 286: 137-46
91. Gower AJ, Noyer M, Verloes R, et al. Ube L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992; 222: 193-203
92. Gower AJ, Hirch E, Boehrer A, et al. Effect of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 1995; 22: 207-13
93. Singh P, Sharief MK, Sander JWA, et al. A pilot study of the efficacy and tolerability of L059 in patients with refractory epilepsy [abstract]. Seizure 1992; 1 Suppl. A: 7/46
94. Chevalier Y, Grant R, Sander WAS, et al. Twelve-week add-on, increasing dose (1,000-4,000 mg/day) multicenter pilot study of ubc L059 in epileptic patients [abstract]. Epilepsia 1995; 36 Suppl. 3: S153
95. De Deyn PP, Bielen E, Saxena V, et al. Assessment of Ihe safety of orally administered UBC L059 as add-on therapy in patients treated with antiepileptic drugs [abstract]. Seizure 1992; 1 Suppl. A: 7/15
96. Leppik IE, Wolff DL. The place of felbamate in the treatment of epilepsy. CNS Drugs 1995; 4: 294-301
97. Reynolds EH. Early treatment and prognosis of epilepsy. Epilepsia 1987; 28: 97-106
98. Elwes RDC, Chesterman P, Reynolds EH. Prognosis after a first untreated tonic-clonic seizure. Lancet 1985; II: 752-3
99. Shorvon SD. The temporal aspects of prognosis in epilepsy. J Neurol Neurosurg Psychiatry 1984; 47: 1157-65
100. Feksi AT, Kaamugisha J, Sander JWA, et al. Comprehensive health care antiepileptic drug treatment programme in rural and semi-urban Kenya. Lancet 1991; 337: 406-9
101. Placencia M, Sander JWAS, Shorvon SD, et al. Antiepileptic drug treatment in a community health care setting in norther Ecuador: a prospective 12-month assessment. Epilepsy Res 1993; 14: 237-44
102. Sander JWAS. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993; 34: 1007-16
103. Watts AE. The natural history of untreated epilepsy in a rural community in Africa. Epilepsia 1992; 33: 464-8
104. Reynolds EH, Chadwick D, Galbraith AW. One drug (phenytion) in the treatment of epilepsy. Lancet 1976; I: 924-6
105. Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy: a reappraisal. CNS Drugs 1995; 3 (3): 194-208
106. Bourgeois BFD. Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction. J Pharmacol Exp Ther 1988; 247: 1128-32
107. Rowan J, Meijer JWA, de Beer-Pawlikowski N. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797-802
108. Fröscher W, Fiaux A, Rothmeier J, et al. Combination of lamotrigine with gamma-Vinyl GABA (vigabatrin) in the management of intractable seizures [abstract]. Epilepsia 1993; 43 Suppl. 2: 158
109. Robinson MK, Black AB, Schapel GS, et al. Combined gamma-Vinyl GABA (vigabatrin) and lamotrigine therapy in the management of refractory epilepsy [abstract]. Epilepsia 1993; 43 Suppl. 2: 109
110. Stolarec I, Blacklaw J, Forrest G, et al. Vigabatrin and lamotrigine m refractory epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 921-4
111. Pisani F, Di Perri R, Perucca E, et al. Interaction of lamotrigine with sodium valproate [letter]. Lancet 1993; 341: 1224
112. Panayiotopoulos CP, Ferrie CD, Knott C, et al. Interaction of lamotrigine with sodium valproate [letter]. Lancet 1993; 341: 445
113. Besag FMC, Panayiotopoulos C, Chivers F, et al. Therapeutic interaction of lamotrigine with valproate and suximides [abstract]. Epilepsia 1995; 36 Suppl. 3: 116
114. Leach JP, Brodie MJ. Synergism with GABAergic drugs in refractory epilepsy [letter]. Lancet 1994; 343: 1650
115. Richens A. Rational polypharmacy. Seizure 1995; 4: 211-4
116. Rodin EA. The prognosis of patients with epilepsy. Springfield (IL): Charles Thomas Publishers, 1968
117. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester. Minnesota, 1935 through 1967. Epilepsia 1975; 16: 1-66
118. Annegers JF, Hauser WA, Elvesback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979; 20: 729-37
119. Goodridge DMG, Shorvon SD. Epileptic seizures in a population of 6000: II. Treatment and prognosis. BMJ 1983; 287: 645-7
120. MRC Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 1991; 337: 1175-80
121. Liu QR, López-Gorcuera B, Mandiyan S, et al. Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain. J Biol Chem 1993; 268: 2106-12
122. Barinaga M. Antibodies linked to rare epilepsy. Science 1995; 268: 362-3